Our newest COVID-19 immunology work is online today at Cell! bit.ly/3mugShW
We aimed to better understand hospitalized COVID-19 cases by examining virus-specific immune responses all in the same people. SARS2-specific Helper T cells, killer T cells, and neutralizing antibodies.
(I.e., measure the adaptive immune response in acute COVID-19 cases with virus-specific tools.)
The three main findings are: 1) Coordinated adaptive immune responses (CD4, CD8, and antibodies together) were associated with reduced COVID-19 disease severity. The adaptive immune system fights the virus well when the 3 branches work together.
2) T cells appear to do the heavy lifting in controlling an active SARS-CoV-2 infection. Virus-specific helper T cells (CD4) and virus-specific killer T cells (CD8) both were significantly associated with lower COVID-19 disease severity.
3) Older people were much less likely to make a coordinated adaptive immune response. It appears that weak or absent T cell responses is a contributing risk factor for why older people are so much more susceptible to severe or fatal COVID-19.
The susceptibility of older people to severe COVID-19 may be, in part, because older people have fewer ’naive’ (inexperienced) T cells, which can make it harder for them to recognize and fight a new virus. cell.com/cell/fulltext/…
We think this work fills an important piece of the COVID-19 puzzle. It looks like the adaptive immune responses are generally a good thing in the fight against this virus, and it is the absence of an adaptive immune response in some people that is a big problem in severe COVID-19
The problem of older people making T cell responses highlights issues to consider in treatment of COVID-19 cases, and the importance of vaccines electing strong immune responses in older people against COVID-19.
Our new paper is out showing T cell responses to the Novavax vaccine, studying Novavax vaccine clinical trial participants, led by the outstanding Dr. @CModerbacher! With a nice commentary article by @PC_immuno . 🧵
The brand newly approved COVID boosters are going to work well. They won’t be a game changer—won’t prevent all infections—but are the best booster option and will provide a lot of protection.
It’s the immunity you want heading into the Fall and winter.
The Omicron booster vaxs are clearly safe. Billions of Covid mRNA vax doses have been given, with excellent safety. Regarding the new “bivalent” boosters, there was a 2021 bivalent COVID booster vax human trial…
Wonderful workshop on Vaccine Durability questions today and yesterday with NIAID. Thanks to my session co-chair @TheBcellArtist, and the awesome panelists. There was intensive and wonderful discussion, and we did make several recommendations 👇🏼
The awesome panelists were @deeptabhattacha@KingLabIPD, Rama Amara, Kanta Subbarao, and Chris Chiu (are they on Twitter?)
The rapid fire recommendations at the end of the discussion:
What kind of studies that would bring us closer to addressing some of the knowledge gaps in engineering durable vaccine immune responses?
We provided the 2x Novavax immunized donor samples, which we extensively compared to mRNA and J&J vaccines for immune memory antibodies, CD4 T cells, CD8 T cells, and memory B cells in a recent paper sciencedirect.com/science/articl…
And it is good to see a new preprint from Penny Moore and colleagues with similar Novavax Omicron data.
What parts of the immune system are protecting you against COVID? Immunology is complicated, so here's a graphic to try and explain it.
Layered defenses against SARS-CoV-2, or the “Swiss cheese” model of immunity.
Multiple types of adaptive immunity with diverse mechanisms likely provide layers of defense against COVID-19. Conceptually, these are like a “Swiss cheese model”: even though each layer is imperfect, together they keep the pathogen from breaching all layers of defense.
The graphic was inspired by the fantastic masking and public health layered defenses Swiss cheese model of @MackayIM.